Table 1 Patient characteristics of the study population
From: Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
Characteristic | Percentage (%)/median (range) | |
|---|---|---|
MDACC (n = 616) | JICR (n = 262) | |
Age (years) | 60.3 (20–92) | 62.1 (22–85) |
Baseline CA-125 level (U/mL) | 800 (7–33423) | 927 (5–24880) |
Nadir CA-125 level (U/mL) | 10 (4–35) | 10 (2–35) |
Ethnic group | ||
 White | 481(78.1) | 0 (0.0) |
 Black | 35 (5.7) | 0 (0.0) |
 Hispanic | 76 (12.3) | 0 (0.0) |
 Eastern Asian | 16 (2.6) | 262 (100.0) |
 Others * | 8 (1.3) | 0 (0.0) |
Surgical residual | ||
 <1 cm | 366 (59.4) | 142 (54.2) |
 1–2 cm | 19 (3.1) | 7 (2.7) |
 >2 cm | 154 (25.0) | 76 (29.0) |
 Unknown | 77 (12.5) | 37 (14.1) |
FIGO stage | ||
 I | 49 (8.0) | 21 (8.0) |
 II | 36 (5.8) | 15 (5.7) |
 III | 410 (66.6) | 171 (65.3) |
 IV | 125 (20.3) | 52 (19.8) |
 Unknown | 4 (0.6) | 2 (0.8) |
Neo-adjuvant chemotherapy | 133 (21.2) | 186 (71.0) |